Clinical Applications of a Peptide-Based Vaccine for Glioblastoma

Charles W. Kanaly, Dale Ding, Amy B. Heimberger, John H. Sampson

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Glioblastoma multiforme is a malignant, relentless brain cancer with no known cure, and standard therapies leave significant room for the development of better, more effective treatments. Immunotherapy is a promising approach to the treatment of solid tumors that directs the patient's own immune system to destroy tumor cells. The most successful immunologically based cancer therapy to date involves the passive administration of monoclonal antibodies, but significant antitumor responses have also been generated with active vaccination strategies and cell-transfer therapies. This article summarizes the important components of the immune system, discusses the specific difficulty of immunologic privilege in the central nervous system, and reviews treatment approaches that are being attempted, with an emphasis on active immunotherapy using peptide vaccines.

Original languageEnglish (US)
Pages (from-to)95-109
Number of pages15
JournalNeurosurgery clinics of North America
Volume21
Issue number1
DOIs
StatePublished - Jan 1 2010

Fingerprint

Subunit Vaccines
Glioblastoma
Immune System
Therapeutics
Active Immunotherapy
Neoplasms
Cell- and Tissue-Based Therapy
Brain Neoplasms
Immunotherapy
Vaccination
Central Nervous System
Monoclonal Antibodies

Keywords

  • Brain neoplasms
  • Epidermal growth factor receptor
  • Glioblastoma
  • Immune system
  • Immunotherapy
  • Neoplasm antigens

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

Clinical Applications of a Peptide-Based Vaccine for Glioblastoma. / Kanaly, Charles W.; Ding, Dale; Heimberger, Amy B.; Sampson, John H.

In: Neurosurgery clinics of North America, Vol. 21, No. 1, 01.01.2010, p. 95-109.

Research output: Contribution to journalReview article

Kanaly, Charles W. ; Ding, Dale ; Heimberger, Amy B. ; Sampson, John H. / Clinical Applications of a Peptide-Based Vaccine for Glioblastoma. In: Neurosurgery clinics of North America. 2010 ; Vol. 21, No. 1. pp. 95-109.
@article{7379a98707714f689a30ca335c9a0f69,
title = "Clinical Applications of a Peptide-Based Vaccine for Glioblastoma",
abstract = "Glioblastoma multiforme is a malignant, relentless brain cancer with no known cure, and standard therapies leave significant room for the development of better, more effective treatments. Immunotherapy is a promising approach to the treatment of solid tumors that directs the patient's own immune system to destroy tumor cells. The most successful immunologically based cancer therapy to date involves the passive administration of monoclonal antibodies, but significant antitumor responses have also been generated with active vaccination strategies and cell-transfer therapies. This article summarizes the important components of the immune system, discusses the specific difficulty of immunologic privilege in the central nervous system, and reviews treatment approaches that are being attempted, with an emphasis on active immunotherapy using peptide vaccines.",
keywords = "Brain neoplasms, Epidermal growth factor receptor, Glioblastoma, Immune system, Immunotherapy, Neoplasm antigens",
author = "Kanaly, {Charles W.} and Dale Ding and Heimberger, {Amy B.} and Sampson, {John H.}",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.nec.2009.09.001",
language = "English (US)",
volume = "21",
pages = "95--109",
journal = "Neurosurgery Clinics of North America",
issn = "1042-3680",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Clinical Applications of a Peptide-Based Vaccine for Glioblastoma

AU - Kanaly, Charles W.

AU - Ding, Dale

AU - Heimberger, Amy B.

AU - Sampson, John H.

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Glioblastoma multiforme is a malignant, relentless brain cancer with no known cure, and standard therapies leave significant room for the development of better, more effective treatments. Immunotherapy is a promising approach to the treatment of solid tumors that directs the patient's own immune system to destroy tumor cells. The most successful immunologically based cancer therapy to date involves the passive administration of monoclonal antibodies, but significant antitumor responses have also been generated with active vaccination strategies and cell-transfer therapies. This article summarizes the important components of the immune system, discusses the specific difficulty of immunologic privilege in the central nervous system, and reviews treatment approaches that are being attempted, with an emphasis on active immunotherapy using peptide vaccines.

AB - Glioblastoma multiforme is a malignant, relentless brain cancer with no known cure, and standard therapies leave significant room for the development of better, more effective treatments. Immunotherapy is a promising approach to the treatment of solid tumors that directs the patient's own immune system to destroy tumor cells. The most successful immunologically based cancer therapy to date involves the passive administration of monoclonal antibodies, but significant antitumor responses have also been generated with active vaccination strategies and cell-transfer therapies. This article summarizes the important components of the immune system, discusses the specific difficulty of immunologic privilege in the central nervous system, and reviews treatment approaches that are being attempted, with an emphasis on active immunotherapy using peptide vaccines.

KW - Brain neoplasms

KW - Epidermal growth factor receptor

KW - Glioblastoma

KW - Immune system

KW - Immunotherapy

KW - Neoplasm antigens

UR - http://www.scopus.com/inward/record.url?scp=70450232004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70450232004&partnerID=8YFLogxK

U2 - 10.1016/j.nec.2009.09.001

DO - 10.1016/j.nec.2009.09.001

M3 - Review article

C2 - 19944970

AN - SCOPUS:70450232004

VL - 21

SP - 95

EP - 109

JO - Neurosurgery Clinics of North America

JF - Neurosurgery Clinics of North America

SN - 1042-3680

IS - 1

ER -